$ABEO

Seshadri Vishwas (Chief Executive Officer) sold 19,608 shares of ABEONA THERAPEUTICS INC. (ABEO) at $5.16 ($0.10M total) on 2026-09-29.

Analysts showed selective bullishness on Sept 25, 2026, with positive calls in tech, healthcare, and industrials. 3M (MMM) was upgraded to Market Perform with a $171 target. ACADIA (ACAD) saw multiple target cuts. Akamai (AKAM) received several target raises. Apple (AAPL) kept Outperform. Chevron (CVX) target raised to $250. Costco (COST) had mixed ratings.

Analysts initiated coverage on five stocks: Abeona (ABEO) with a $17 target, NexGen (NXE) at $14, Nano Nuclear (NNE) at $33, SanDisk (SNDK) at $2,400, and Tempus (TEM) at $75. Abeona's ZEVASKYN gene therapy, NexGen's uranium project, Nano Nuclear's KRONOS reactor, SanDisk's AI infrastructure, and Tempus's diagnostics business are key focuses.

Several biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.

Analysts updated ratings for five stocks: Rocket Pharmaceuticals (RCKT) was upgraded to Buy with a $9 target due to FDA confidence in its Danon disease study. Copart (CPRT) was downgraded to Hold with a $36 target due to weak insurance volumes and rising costs. Pegasystems (PEGA) was downgraded to Neutral with a $47 target due to AI-related disruption. Abeona Therapeutics (ABEO) was initiated with a Buy and $17 target due to strong gene therapy prospects. Fluence Energy (FLNC) was downgraded to

Cantor Fitzgerald raised its price target on Abeona Therapeutics (NASDAQ:ABEO) to $30 from $28, citing its partner Ultragenyx's drug approval. Abeona is eligible for royalties and milestone payments. Q2 2026 revenue was $11.4M, below estimates, with a net loss of $20.2M. Roth/MKM initiated coverage with a Buy rating and $17 target.

Abeona Therapeutics (ABEO) congratulated Ultragenyx (RARE) on FDA approval of FAYUVI, a gene therapy for Sanfilippo syndrome type A (MPS IIIA). Abeona initially developed the therapy and licensed it to Ultragenyx in 2022, making it eligible for milestone payments and royalties. FAYUVI addresses a rare, progressive neurodegenerative disease with high unmet medical need.

Abeona Therapeutics (ABEO) reported Q2 revenue of $11.4M, up 31% from Q1, driven by its gene therapy ZEVASKYN. The company treated 12 patients, with 5 in Q2 and 3 more in Q3 to date. It secured a new technology add-on payment from CMS. However, net loss widened to $20.2M, and cancellations due to manufacturing issues were noted.

Abeona Therapeutics reported treating 12 patients since launch, with 5 in Q2 2026, but revenue recognized for only 4 due to manufacturing variability. It activated 7 qualified treatment centers by year-end goal. Q2 gross margin was 63%, with normalized 85% to 90% expected. Cash was $146.8M at June 30, 2026. CMS NTAP starts Oct 1, 2026.

Abeona Therapeutics (ABEO) reported Q2 2026 results showing a swing to a net loss of $20.19M, or $0.35/share, versus net income of $108.83M, or $1.71/share, a year earlier largely due to a $152.37M priority review voucher gain. Q2 revenue rose to $11.38M from $0.40M. Cash totaled $146.8M as of June 30. ZEVASKYN treated 5 patients in Q2.